GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.00
+0.12 (+0.30%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close39.88
Open39.95
Bid0.00 x 0
Ask0.00 x 0
Day's Range39.88 - 40.13
52 Week Range34.52 - 44.54
Volume2,924,227
Avg. Volume3,588,961
Market Cap95.467B
Beta0.70
PE Ratio (TTM)45.77
EPS (TTM)0.87
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield2.55 (6.29%)
Ex-Dividend Date2018-02-22
1y Target Est40.43
Trade prices are not sourced from all markets
  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zacks18 hours ago

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

  • Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)
    Motley Fool22 hours ago

    Better Buy: GlaxoSmithKline plc (GSK) vs. Eli Lilly (LLY)

    Which stock wins in a head-to-head matchup of these two big pharma companies?

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks2 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • GlobeNewswire2 days ago

    NeuroMetrix Reports Q1 2018 Financial Results

    WALTHAM, Mass., April 19, 2018-- NeuroMetrix, Inc., today reported financial and business highlights for the quarter ended March 31, 2018.. The Company develops and markets novel therapies, based on neurostimulation ...

  • Reuters3 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline (GSK.L), which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca (AZN.L) and Novartis (NOVN.S), and it showed benefits over other treatments in the study.

  • Business Wire3 days ago

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Reuters3 days ago

    Experts query case for GlaxoSmithKline's new 3-in-1 lung drug

    Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition. Trelegy Ellipta was licensed for use last year and full results from a positive clinical trial were published on Wednesday in the New England Journal of Medicine (NEJM). Trelegy is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting GSK ahead of rivals such as AstraZeneca and Novartis, and it showed benefits over other treatments in the study.

  • GSK flags pharma M&A ambitions by poaching Roche deal-maker
    Reuters3 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline (GSK.L) signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's (ROG.S) Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters3 days ago

    GSK flags pharma M&A ambitions by poaching Roche deal-maker

    GlaxoSmithKline signalled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche's Genentech unit to lead a worldwide search for promising experimental products. Barron is also a veteran of Genentech, famous for its biotech cancer medicines.

  • Reuters3 days ago

    GSK grabs Roche cancer expert to lead pharma pipeline deals

    GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Roche's Genentech unit to head worldwide business development for pharmaceuticals research and development. Sin, who will join GSK in San Francisco ...

  • Novartis’s 1Q18 Estimates: Expectations for Alcon
    Market Realist3 days ago

    Novartis’s 1Q18 Estimates: Expectations for Alcon

    Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.

  • Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
    Bloomberg3 days ago

    Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria

    GlaxoSmithKline Plc and Novartis AG will contribute research funds to an almost $4 billion global effort to combat malaria as drug-resistant strains of the disease threaten to undo years of progress.

  • Expectations from Novartis’s 1Q18 Earnings
    Market Realist4 days ago

    Expectations from Novartis’s 1Q18 Earnings

    Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.

  • GlobeNewswire5 days ago

    Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting

    -Preclinical testing raises no safety concerns for MAGE A4-- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity-. PHILADELPHIA, Pa. and OXFORD, United ...

  • Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz
    Investor's Business Daily8 days ago

    Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz

    Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.

  • Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
    Zacks8 days ago

    Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III

    Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.

  • Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
    Zacks8 days ago

    Glaxo to Sell Rare Disease Gene Therapies to Private Biotech

    Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.

  • GSK divests its rare disease gene therapy portfolio
    American City Business Journals9 days ago

    GSK divests its rare disease gene therapy portfolio

    The Big Pharma company is getting a 20 percent equity stake in a London gene therapy company. GSK said it plans to focus its cell and gene therapy research on new treatments for cancer.

  • Reuters9 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline (GSK.L) is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • Reuters9 days ago

    GSK slims portfolio with sale of rare disease gene therapy drugs

    GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker's pharmaceuticals portfolio. Financially, the transaction will not move the dial for Britain's biggest drugmaker, but it offers a sign that Walmsley is making progress in reshaping the company since her arrival a year ago.

  • GlaxoSmithKline Buys Novartis’s Stake in Joint Venture
    Market Realist9 days ago

    GlaxoSmithKline Buys Novartis’s Stake in Joint Venture

    On March 27, 2018, GlaxoSmithKline (GSK) announced an agreement with Novartis (NVS) to buy Novartis’s stake in their consumer healthcare joint venture. GlaxoSmithKline will pay $13 billion for Novartis’s 36.5% stake.

  • Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN
    Zacks9 days ago

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

    Zacks Market Edge Highlights: Exxon, Diageo, GlaxoSmithKline, Micron and AMN

  • MarketWatch9 days ago

    U.K. stocks waver as traders remain wary over Syria conflict

    U.K. stocks struggle for direction on Thursday, as investors remain nervous over the potential for a military conflict in Syria and digested the latest Federal Reserve minutes.

  • Reuters9 days ago

    UK gene therapy firm Orchard plans stock offer after GSK deal

    Britain's Orchard Therapeutics, which has already raised more than $140 million (98.54 million pounds) to fund its work in gene therapy, plans another private sale of shares following its acquisition of a portfolio of GlaxoSmithKline (GSK.L) rare disease medicines. Chief Executive Mark Rothera also told Reuters that an initial public offering (IPO) was an option beyond this next private financing move. Gene therapy is a hot area for drug research - highlighted by Novartis's (NOVN.S) $8.7 billion acquisition of AveXis (AVXS.O) this week - but the rare disease products sold to Orchard are too niche for GSK as it refocuses its R&D efforts.

  • Financial Times9 days ago

    [$$] GSK sells rare disease gene therapy portfolio

    GlaxoSmithKline has offloaded its rare disease gene therapy portfolio to the biotechnology company Orchard Therapeutics, in exchange for a near-20 per cent stake in the two-year-old business. A sale of ...